Geron Corporation (BIT:1GERN)

Market Cap	717.03M
Revenue (ttm)	140.03M
Net Income (ttm)	-74.94M
Shares Out	n/a
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	200
Open	1.150
Previous Close	1.150
Day's Range	1.150 - 1.150
52-Week Range	1.000 - 1.390
Beta	n/a
RSI	12.76
Earnings Date	Nov 6, 2025

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 229
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1GERN

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial numbers in USD